Clinical trials update from the American Heart Association meeting: Ω-3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PAD and DEFINITE

European Journal of Heart Failure

Volumn 6, Issue 1, 2004, Pages 109-115

  Cleland, John G F ^a   Freemantle, Nick ^b   Kaye, Gerry ^a   Nasir, Mansoor ^a   Velavan, Periaswamy ^a   Lalukota, Krishna ^a   Mudawi, Telal ^a   Shelton, Rhidian ^a   Clark, Andrew L ^a   Coletta, Alison P ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

3 fatty acids; ACTIV in CHF; DEFINITE; ORBIT; PAD; SPORTIF V; The Hanover Autologous Bone Marrow Transplantation Study; VALIANT

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LIVER ENZYME; LOSARTAN; OMEGA 3 FATTY ACID; SPIRONOLACTONE; THROMBIN INHIBITOR; TOLVAPTAN; VALSARTAN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR; WARFARIN; XIMELAGATRAN;

ACUTE HEART INFARCTION; ANGIOPLASTY; ARTICLE; BLEEDING; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CARDIOVERSION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; COUGHING; DEFIBRILLATION; DEFIBRILLATOR; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; FOLLOW UP; HEALTH PROGRAM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REPERFUSION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; KIDNEY DISEASE; MORTALITY; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RECEPTOR BLOCKING; RESUSCITATION; SIDE EFFECT; STENT; STROKE; SUDDEN DEATH; TASTE DISORDER; THIRST; VASOPRESSIN BLOOD LEVEL; WEIGHT REDUCTION;

ANTIHYPERTENSIVE AGENTS; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS; ELECTRIC COUNTERSHOCK; FATTY ACIDS, OMEGA-3; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, VASOPRESSIN; THROMBIN;

EID: 10744224064     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2003.12.002     Document Type: Article

References (24)

1. Marchioli R., Barzi F., Bomba E., et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 105:(16):2002;1897-1903.
2. Cleland J.G.F., Massie B.M., Packer M. Sudden death in heart failure: vascular of electrical? Eur J Heart Fail. 1:1999;41-45.
3. 2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 104:2001;2417-2423.
4. Francis G.S., Benedict C., Johnstone D.E., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A sub-study of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 82:1990;1724-1729.
5. Dickstein K, Kjekshus J and the OPTIMAAL Steering Committee for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360(9335):752-60.
6. Velazquez EJ, Pfeffer MA, McMurray JV, et al. VALsartan in Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail 2003;(4):537-544.
7. Pfeffer M.A., McMurray J.J.V., Velazquez E.J., et al. Valsartan, Captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med. 349:2003;1893-1906.
8. Cohn JN, Tognoni G, for the Valsartan Heart Failure Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345(23):1667-1675.
9. McMurray J.J.V., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 362:(9386):2003;767-771.
10. Orlic D., Kajstura J., Chimenti S., et al. Bone marrow cells regenerate infarcted myocardium. Nature. 410:(6829):2001;701-705.
11. Kamihata H., Matsubara H., Nishiue T., et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation. 104:(9):2001;1046-1052.
12. Strauer B.E., Brehm M., Zeus T., et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 106:(15):2002;1913-1918.
13. Assmus B., Schachinger V., Teupe C., et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 106:(24):2002;3009-3017.
14. Britten M.B., Abolmaali N.D., Assmus B., et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation. 108:(18):2003;2212-2218.
15. Petersen P., Boysen G., Godtfredsen J., Andersen E.D., Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1:(8631):1989;175-179.
16. Cleland J.G., Coletta A.P., Nikitin N., Louis A., Clark A. Update of clinical trials from the American College of Cardiology . EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans. Eur J Heart Fail. 5:(3):2003;391-398.
17. Halperin JL, Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003;146(3):431-8.
18. Moss A.H.J., Hall W.J., Cannom D.S., et al. Improved survival with an implantable defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 335:1996;1933-1940.
19. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 346:2002;877-883.
20. Bigger JTJ, for the Coronary Artery Bypass Graft (CABG) Patch trial investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997;337(22):1569-75.
21. Strickberger SA, Hummel JD, Bartlett TG, et al, for the AMIOVIRT Investigators. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol 2003;41(10):1707-12.
22. Bansch D, Antz M, Boczor S, et al, for the CAT investigators. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy. The Cardiomyopathy trial (CAT). Circulation 2002;105:1453-8.
23. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator. The dual chamber and VVI implantable defibrillator (DAVID) trial. J Am Med Assoc. 288:2002;3115-3123.
24. Boutite F., Boissel J.-P., Connolly S.J., et al. Amiodarone interaction with beta-blockers. Analysis of the merged EMIAT and CAMIAT databases. Circulation. 99:1999;2268-2275.